Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape.
Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.
Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG
AB Science SA
Acceleron Pharma Inc
ACROVIS Pharma AG
Adaptimmune Therapeutics Plc
Aduro BioTech Inc
Advenchen Laboratories LLC
Alfact Innovation
Alissa Pharma
Alnylam Pharmaceuticals Inc
American Gene Technologies International Inc
Amgen Inc
AndroScience Corp
APAvadis Biotechnologies Srl
ArQule Inc
Array BioPharma Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Betta Pharmaceuticals Co Ltd
Bio-Cancer Treatment International Ltd
BioCancell Ltd
Biogazelle NV
Biomics Biotechnologies Co Ltd
Bioneer Corp
BioStar Pharmaceuticals Inc
BLR Bio LLC
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Boston Biomedical Inc
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd
CASI Pharmaceuticals Inc
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Celldex Therapeutics Inc
Celprogen Inc
Celsion Corp
China Medical System Holdings Ltd
Chiome Bioscience Inc
Chipscreen Biosciences Ltd
Chroma Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
CohBar Inc
CZ BioMed Corp
Daiichi Sankyo Company Ltd
Delcath Systems Inc
Dicerna Pharmaceuticals Inc
Double Bond Pharmaceutical International AB
Eisai Co Ltd
Eli Lilly and Company
Endocyte Inc
Epeius Biotechnologies Corp
eTheRNA Immunotherapies NV
Eureka Therapeutics Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Formosa Laboratories Inc
Galaxy Biotech LLC
Genelux Corp
Genoscience Pharma
Genosco Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Golden Biotechnology Corp
Green Cross Cell Corp
Green Cross Corp
H3 Biomedicine Inc
HanAll Biopharma Co Ltd
HEC Pharm Co Ltd
HitGen LTD
Horizon Pharma Plc
Immune Therapeutics Inc
Immunicum AB
Immunitor Inc
Immunomedics Inc
Immunophotonics Inc
Immunovative Therapies Ltd
IMPACT Therapeutics Inc
In-Cell-Art SAS
Incanthera Ltd
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
InteRNA Technologies BV
Intezyne Technologies Inc
Jasco Pharmaceuticals LLC
Jenrin Discovery Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JW Pharmaceutical Corp
KAHR medical Ltd
Karcinolys SAS
Keystone Nano Inc
Kite Pharma Inc
Komipharm International Co Ltd
Kowa Company Ltd
Les Laboratoires Servier SAS
Lidds AB
Ligand Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Lytix Biopharma AS
MaxCyte Inc
MedImmune LLC
Medivation Inc
Medivir AB
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Molecular Partners AG
MultiCell Technologies Inc
NormOxys Inc
Northwest Biotherapeutics Inc
Novartis AG
NovaTarg Therapeutics Inc
Nymox Pharmaceutical Corp
Omeros Corp
Omnitura Therapeutics Inc
Oncolys BioPharma Inc
OncoMed Pharmaceuticals Inc
OncoTherapy Science Inc
Oneness Biotech Co Ltd
Ono Pharmaceutical Co Ltd
Onxeo SA
OPKO Health Inc
Oribase Pharma
OSE Immunotherapeutics
Otsuka Holdings Co Ltd
Panacea Pharmaceuticals Inc
Peptinov SAS
PepVax Inc
Peregrine Pharmaceuticals Inc
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
PharmaEssentia Corp
Phosplatin Therapeutics LLC
ProMetic Life Sciences Inc
Provecs Medical GmbH
Provectus Biopharmaceuticals Inc
RedHill Biopharma Ltd
Regen BioPharma Inc
Regulus Therapeutics Inc
Rigontec GmbH
Samumed LLC
Saronic Biotechnology Inc
Savoy Pharmaceuticals Inc
Shenogen Pharma Group Ltd
Shenzen SiBiono GeneTech Co Ltd
Silence Therapeutics Plc
Sillajen Biotherapeutics
Simcere Pharmaceutical Group
Somantix BV
Sorrento Therapeutics Inc
Synovo GmbH
TaiRx Inc
Taiwan Liposome Company Ltd
Tara Immuno-Oncology Therapeutics LLC
Targetome SA
TC BioPharm Ltd
Tessa Therapeutics Pte Ltd
Therapure Biopharma Inc
Theravectys SA
Threshold Pharmaceuticals Inc
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
Transgene Biotek Ltd
Tumorend LLC
UbiVac LLC
VasGene Therapeutics Inc
Vaxon Biotech
Vect-Horus SAS
Verlyx Pharma Inc
VG Life Sciences Inc
Vicus Therapeutics LLC
Virttu Biologics Ltd
